Home > Blog > Advanced Therapies & Technology A remote oncology consultation can provide another specialist’s perspective without requiring the patient to travel immediately. Its usefulness, however, depends partly on whether the specialist receives relevant medical records and clearly prioritised questions. The most useful remote oncology consultation questions go beyond asking, “What treatment do you recommend?” They should clarify what the submitted records show, what rema

Home > Blog > Advanced Therapies & Technology In an oncology record, the difference between PD-1 and PD-L1 may appear to be only two characters. Clinically, however, the terms do not describe the same protein, the same drug target, or the same type of medical information. PD-1 is an immune checkpoint receptor found on immune cells, including T cells. PD-L1 is one of the proteins that can bind to PD-1. Some medicines block PD-1, while others block PD-L1. The distinction become

Home > Blog > Advanced Therapies & Technology Finding a gene alteration in a cancer report can appear to offer a clear next step: identify the mutation, locate a medicine that targets it, and begin treatment. In practice, the relationship between a cancer mutation and targeted therapy is more complex. A tumor genomic report may identify mutations, deletions, amplifications, fusions, and other biomarkers. However, detecting an alteration does not automatically prove that it dr

Home > Blog > Advanced Therapies & Technology When a cancer diagnosis is complex, treatment options appear limited, or the disease has progressed despite therapy, patients and families may begin exploring specialists and hospitals in other countries. China may be considered because its major oncology centers include disease-specific specialists and treatment pathways that may differ from those previously discussed with the patient. But finding another possible treatment appro

Home > Blog > Advanced Therapies & Technology Key Takeaways The Chinese healthcare system provides structured pathways to access innovative medicines through National Medical Products Administration (NMPA) approvals and special medical zones. While 3,159 medicines are included in the national reimbursement catalog, institutional availability depends on specific hospital formularies and centralized procurement cycles. For some medicines and indications, public medicine pri

Home > Blog > Advanced Therapies & Technology Key Takeaways Amimestrocel (trade name: 睿铂生; transliterated as Ruibosheng) has received conditional approval from the Chinese National Medical Products Administration (NMPA) for a highly specific hematological indication. It is restricted to patients aged 14 and older with steroid-refractory acute graft-versus-host disease (SR-aGVHD) predominantly involving the gastrointestinal tract. The publicly reported medicine price in Ch

Home > Blog > Advanced Therapies & Technology Key Takeaways China has approved lecanemab and donanemab for selected patients with early symptomatic Alzheimer’s disease. In practice, these treatments are generally delivered through hospitals with specialist neurology, infusion, biomarker-testing, and MRI-monitoring capabilities. Important: These medicines do not cure Alzheimer’s disease and are intended only for selected patients in the early symptomatic stage with confirmed

Home > Blog > Advanced Therapies & Technology Key Takeaway Targeted Dose Distribution: Particle therapy leverages the Bragg-peak effect to create a sharp distal fall-off, which may reduce radiation exposure to selected nearby healthy tissues compared to conventional X-ray therapy. Advanced Clinical Infrastructure: China has developed multiple specialized proton and carbon-ion treatment centers in several major cities, providing clinical access to modalities evaluated for spec

Home > Blog > Advanced Therapies & Technology Quick Answer For international patients, Boao Lecheng special access is a regulated, case-by-case pathway. The process may involve: Organizing and, where required, translating medical records according to the receiving institution’s submission requirements. Submitting records for a preliminary clinical and administrative feasibility review. Confirming whether the requested medicine or device is currently available through an a

Home > Blog > Advanced Therapies & Technology Who This Article Is For This article is intended for international patients and families researching deep brain stimulation in China as an advanced assessment pathway after Parkinson’s symptoms have become difficult to manage. It does not determine whether an individual is suitable for surgery. Access Context: A 2024 comparative study indicated that New Zealand had one of the lowest reported DBS utilisation rates among the high-in

Home > Blog > Advanced Therapies & Technology Navigating CAR-T Cell Therapy Options in China When Standard Therapies Fail Key Takeaways Patients with relapsed or refractory hematological malignancies may explore commercial CAR-T cell therapy options in China through specialized clinical hubs. Clinical centers in Beijing are reported to have a high concentration of dual-target CAR-T research and clinical application experience. Reported estimates for commercial CAR-T therapies

Home > Blog > Advanced Therapies & Technology Key Takeaways: The Boao Lecheng pilot zone has reportedly introduced over 557 overseas-approved innovative medicines and devices, though access depends strictly on hospital review and clinical eligibility. Administrative review for eligible "clinical urgent need" products is often described as taking 3 to 7 working days after institutional submission, subject to institutional scheduling policies and product availability. In el

Home > Blog > Advanced Therapies & Technology Key Takeaways: Patients with refractory Claudin 18.2-positive, HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma may seek a multidisciplinary review in China to evaluate eligibility for newly approved cellular therapies. Medical visa applications require formalized institutional acceptance letters, structured medical records, and specific high-liquidity financial documentation. Institutional protocols enf

Home > Blog > Advanced Therapies & Technology Key Takeaways International patients should be reviewed against aviation, clinical, and institutional baseline requirements before making travel plans. Accessing advanced therapies requires complete, translated dossiers including DICOM imaging and original pathology reports. A structured medical travel to China safety checklist helps organize documents and identify clinical red flags that may preclude safe travel. Quick Answ

Home > Blog > Advanced Therapies & Technology Key Takeaways AstraZeneca is developing a commercial manufacturing base in Guangzhou, China, focused on next-generation radioconjugate drugs, including Actinium-225 targeted therapies. Actinium-225 is an alpha-emitting isotope that induces irreversible double-strand DNA breaks in tumor cells while protecting adjacent healthy tissues due to its extremely short tissue range of 40 to 85 micrometers. Navigating institutional revie

Home > Blog > Advanced Therapies & Technology Key Takeaways Major licensing agreements between global pharmaceutical companies and Chinese biotech firms typically involve compounds in early-stage discovery or clinical development, not commercially available therapies. For international patients, access to investigational oncology programs in China is not automatic and is heavily restricted by institutional criteria, ethics reviews, and specific biomarker requirements. A r

Home > Blog > Advanced Therapies & Technology Key Takeaways Clinical data presented at ASCO 2026 indicated that the antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT), combined with pembrolizumab, reduced the risk of disease progression in a specific, previously untreated cohort of patients with advanced non-small cell lung cancer (NSCLC). Access to advanced ADC protocols in China requires documented biomarker evidence, protocol-specific eligibility review, and

Home > Blog > Advanced Therapies & Technology Key Takeaways China hosts approximately 40% of global oncology clinical trials, with a heavy concentration in cellular therapies, antibody-drug conjugates (ADCs), and bispecific antibodies. Eligibility for these experimental protocols is rigorously dictated by precise molecular profiling, previous lines of therapy, and strict physical performance scores. Biological samples and genomic data generated, stored, retested, or trans

Home > Blog > Advanced Therapies & Technology Key Takeaways The Chinese National Medical Products Administration (NMPA) approved satricabtagene autoleucel (satri-cel) as a cellular pathway for patients with Claudin18.2 (CLDN18.2) positive, HER2-negative advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have failed at least two prior systemic therapies. Accessing this specialized pathway requires rigorous biomarker confirmation, including the translation

Home > Blog > Advanced Therapies & Technology What Are the Administrative Pathways for Advanced Radiotherapy in China? Key Takeaways China has approved advanced radiotherapy systems, including proton therapy, carbon-ion therapy, and MRI-guided radiotherapy platforms, but these technologies are concentrated within specialized tertiary cancer centers. International patient access is reviewed by hospital specialist departments and depends on case suitability, documentation compl